Obesity is a disease with many comorbidities, some of which increase perioperative risk and most of which are improved or even cured by weight loss effectively achieved by surgery. Since anti-obesity surgery is 'behavioral surgery', outcome is independent of the technical performance of the operation and patient selection is critical. Pre-and postoperative patient education is more important than in other gastrointestinal surgery. For example, knowledge of the 'Rules of eating' and the 'Rules of vomiting' are essential for outcome of gastric restrictive surgery.
Introduction
The overall objectives of surgeons' selection of patients are two-fold: (1) maximize perioperative safety; and (2) optimize long-term outcome. Obese patients having anti-obesity surgery pose special problems because of the pathophysiology of obesity and its influence on anesthesia, conduct of the operation and postoperative resuscitation, and because the long-term outcome for the most part is independent of the technical performance of the operation. The factors influencing long-term outcome are important for many types of surgery, but outcome of bariatric surgery to a greater extent than other fields is judged over a very long period of time and by different standards.
According to the American College of Surgeons (ACS) Statement on Principles Underlying Perioperative Responsibility: 'The surgeon is responsible for the preoperative preparation of the patient. Minimizing the risk of operation while providing maximal opportunity for a satisfactory outcome, requires a full appreciation by the surgeon of the patient's condition'. 1 How does this pertain to selection of patients for anti-obesity surgery? Clearly patient selection is an important component in achieving a 'satisfactory outcome' in all types of surgery, but optimal outcome has not been sufficiently defined in surgical trials in general 2 and in anti-obesity surgery in particular: there is only limited data on patient selection in this context. This presentation will not discuss optimization of physiological parameters relevant to anesthesia and medical management or perioperative safety, the objective of the ACS statement above. The readers are referred to other texts for this purpose. 3, 4 Instead, this is a presentation of indications and an attempt to analyze factors of importance in selecting patients for optimal long-term outcome, encompassing the goals of comorbidity reduction and prolongation of qualityadjusted life years (so-called QALY 5 ), most easily understood as provision of patient satisfaction.
Critical differences between bariatric surgery and most other forms of surgery are the facts that it is 'behavioral' surgery, it does not have curative intent in the absence of any known etiology of obesity, and it is not reconstructive in the common meaning of the word. Furthermore, optimization of long-term 'satisfactory outcome' requires more pre-and postoperative patient education than most other surgery. Realization of these facts helps to explain much of the controversy over the surgery, particularly among surgeons, and the perception that 'results' are poor, leading to frequent modifications in techniques through the years.
Indications
Before discussing indications for surgery it behooves us to analyze some basic premises for severely obese patients to undergo anti-obesity surgery (Table 1 ). Item 1 presupposes that an inability to control food intake is inherent in the condition of severe or 'morbid' obesity. Binge-eating disorder (BED) is more prevalent 6 and more severe 7 with increasing body mass index (BMI). Item 2 includes the patient's tacit or expressed desire to reach a 'goal' weight. It is important to explore the patient's true motives and possible ambivalence about losing weight (Table 2 ). Of particular concern is the attitude or support of a partner or spouse since weight loss seriously influences inter-personal relationships. 8 Furthermore, assessment of whether the patient's goals are realistic or 'healthy' must be included.
The risk -benefit analyses in item 3 should be based on an understanding of the risks of remaining unoperated or 'treated' by non-surgical methods and the benefits in net morbidity, prolongation of life or improvement in quality of life (whether health-related or other). Trade-offs in quality of life must be analyzed. 9 Item 4 includes costs of nontreatment with its attendant present and future morbidity, which complicates the econometric analysis.
Old indications for surgery
It is important to know the history of the evolution of indications and contraindications for bariatric surgery in order to understand the current debate on the topic. 'Morbid' obesity, defined as 100 lb (45.4 kg) above ideal or desirable weight for height according to the Metropolitan Life Insurance Company (USA) actuarial tables of minimum mortality, and also defined as twice 'ideal' weight, was introduced as a term designating patients who were candidates for intestinal bypass operations in the sixties. 10 Other 'requirements' for having surgery included a duration of obesity of 2 -5 y, a history of multiple failures of physiciansupervised weight loss, psychiatric evaluation 'clearing' the patient for surgery, and absence of alcoholism or drug abuse. 11, 12 Occasionally absence (sic!) of cardio-pulmonary disease was also proposed as a requirement.
Who promulgated these requirements or guidelines? This is not clear. Dr Payne, the champion of the jejuno-ileal bypass, is 'credited' with inventing the term 'morbid obesity' to convince insurers of the existence of a special form of obesity, deserving of surgical intervention. 10 It is likely that the criteria listed above evolved through third party payers and their physician consultants, exclusively internists. At the time, there was no evidence to support these guidelines, yet they were more or less strongly enforced for reimbursement purposes for many years and some of them are still used by insurance companies mainly to limit or delay the provision of services.
'New' indications for surgery
The indications for surgery evolved during the eighties from those summarized above to the ones formulated in the NIH Consensus Development Conference, Gastrointestinal Surgery for Severe Obesity, in 1991. 13 The changes were largely brought about owing to the increased awareness of the seriousness of obesity with respect to both prevalence and morbidity, identification of the ineffectiveness of nonsurgical treatments and to the development of safer gastric procedures.
The weight criterion, now expressed in terms of body mass index, was broadened to include manifest comorbidity present at BMI 35 kg=m 2 . The requirement of a duration of obesity of 5 y or more was dropped in recognition of the fact that severe obesity takes many years to develop and most prevalently is of juvenile onset. Instead of 'documented failure of other measures' the 1991 Consensus statement suggested that 'patients seeking treatment for the first time should be considered' for a nonsurgical program at the discretion of their physician. 13 The mandate to perform psychiatric evaluation of 'emotional stability' was replaced by the proposal that surgical candidates be evaluated 'by a multi-disciplinary team with medical, surgical, psychiatric and nutritional expertise'. Though there is no evidence to support this seemingly reasonable approach improving patient selection, availability of such a multi-disciplinary team postoperatively can benefit the long-term management of these complex patients. Appropriately the consensus panel insisted that Table 1 Premises of candidacy for bariatric surgery 1 Demonstrated inability to adequately control food intake 2 Expression of real desire to lose weight 3 Personal risk -benefit analysis comparing surgery to other treatment or nontreatment 4 Personal cost -benefit analysis including cost of treatment of comorbidity anti-obesity surgery only be performed in a clinical setting with adequate support and that life-long medical surveillance is a necessity. In the context of patient selection it was suggested that candidates be evaluated with respect to their ability 'to comply adequately with the postoperative regimen'. Unfortunately there are no validated methods for performing such an evaluation.
On the topic of patient selection or outcomes, the 1991 NIH conference statement correctly concluded that data were lacking for making 'recommendations for patient selection using objective clinical features alone'. However, the statement was made concerning the choice of surgical treatment over other treatment notwithstanding that the panel had heard summaries of beneficial outcomes of numerous surgical series followed for more than 10 y with significant reductions in comorbidity accompanying maintained weight loss. The critical issue seemed to be the absence of controlled studies. This concept was repeated in the Consensus panel's recommendations for future clinical research, which called for comparisons 'with an appropriate comparison group'. This recommendation also seems reasonable, but does not stand up to close scrutiny.
Randomized trials
Internists often require prospective randomized controlled trials to evaluate any treatment. They have been particularly persistent in requiring such trials of anti-obesity surgery. This proposition, however, is seriously flawed: a prime ethical requirement of randomization is that both the subject and the investigator are convinced of the equivalence of the treatment options being chosen by chance. Such equivalence should pertain to both perceived efficacy and perceived risk of the options.
Prima facie, when risks of surgery are compared to those of any nonsurgical treatment, these risks are never perceived as equivalent, at least not over the short term to which most people are able to relate. Even if the time frame is fully explained and understood, it is human nature to opt for short-term solutions (maximum of 5 y) in most instances. However, a short-term perspective is inappropriate. For example, nonoperative treatment of obesity is likely to fail beyond 1 y ( > 95% failure rate). The failure can have two outcomes: (1) prolonged exposure to the inherent risks of the disease; and (2) postponement of effective treatment worsening the patient's condition, putting her=him at greater risk for the surgery than originally was the case. Both of these outcomes are unethical.
The same reasoning pertains to efficacy. Postponing effective treatment may deprive the patient of the opportunity for reversing a condition known to progress to irreversibility (eg diabetes, with exhaustion of pancreatic reserves).
From a scientific viewpoint randomization is also flawed. Randomization should guarantee similar compliance or adherence among the groups being studied, since high drop-out rates jeopardize adequate evaluation of a treatment arm. A high failure rate of one arm of a trial compromises the ability to perform a valid long-term comparison.
Scientifically, study participants should be representative of the population about which inferences are being made. In contrast to placebo-controlled blinded drug studies, trials of surgical treatment have higher compliance rates. This phenomenon is well-known from purely pharmacological trials where treatment arms with drugs with potent subjective effects are more likely to retain subjects than placebos. Drop-out rates are much higher with less effective treatment than with surgery because of the stronger positive or negative motivational factors involved in surgical treatment: positive as perceived benefit, negative as fear of consequences of noncompliance.
There is always a risk of selection bias in any trial where subjects might perceive themselves as 'chosen', thus motivating them to be more compliant than the controls. With the powerful treatment effects of surgery, such selective subject participation is very likely. Interestingly, selection bias seems to pertain to all treatment of obesity.
14 For the reasons outlined above, it should be clear that it is unreasonable to demand prospective randomized controlled trials (PRCT) to evaluate any surgical treatment modality compared to the mostly ineffective nonsurgical options and even less, to placebo. Indeed, it is debatable whether PRCT can be performed between substantially different surgical modalities (eg gastroplasty vs gastric bypass). The alternative for surgical trials, albeit imperfect, is observational studies as has been suggested by Hu et al. 15 Though criticized for being biased in favor of treatment options, recent meta-analytic studies have not detected differences between randomized and observational studies. 16 
Evolving indications
In spite of significant advances in the understanding of the molecular biology of adipose tissue, appetite regulation and energy balance, and developments of new drugs, there is as yet no evidence for realistic nonoperative treatment of obese patients with BMI of 32 and higher. The 'accepted' minimum BMI criteria in the United States has been 35 kg=m 2 in the presence of manifest serious comorbidity. 13 In many European countries a BMI of 35 has been accepted without the requirement for manifest comorbidity and, indeed, the nationwide Swedish Obese Subjects (SOS) study accepts men with a BMI of 34. 17 With demonstrations that the duration of exposure to obesity decreases the likelihood of durable remission or cure, 18 it appears that an argument can be made for early intervention. 'Early' in this context means shortly after a critical BMI has been reached in analogy with early treatment of diabetes. 19 The complex issue of minimum age or maturity level to undergo anti-obesity surgery has not been studied sufficiently to provide age criteria, though one excellent study demonstrates favorable long term outcome in adolescents aged 11 -19 y. 20 Thus it would seem that lower BMI levels are being accepted, partly through recognition of the intractability of the disease, the need for prevention of comorbidity and the increased safety introduced via laparoscopic techniques. 21 Awareness of the serious impact of obesity on quality of life 22 and socio-economic parameters 23 has broadened the scope of factors included among indications for anti-obesity surgery. Critical to the formulation of any indications is the need for outcome predictors to guide in the selection of patients.
Outcomes and predictors
There are many different types of outcomes after anti-obesity surgery: perioperative and postoperative complications and side-effects, weight loss maintenance, co-morbidity reduction, econometric changes, psychosocial adaptation and objective and subjective quality-of-life changes. It is true that many are inter-correlated and are related to loss of excess body weight, but weight loss alone is an inadequate outcome measure. Just as 'quality of life' is multidimensional 22 so is the definition of 'successful outcome', 24, 25 making it particularly difficult to identify predictors useful for patient selection.
There are five categories of problems associated with poor long term outcomes of anti-obesity surgery: (1) inadequate patient knowledge; (2) psychosocial maladaptation; (3) anatomic complications; (4) gastrointestinal pathophysiology; and (5) weight-related symptomatology. 26 There is considerable interaction and overlap among these categories.
The most important behavioral aspects of preparing a severely obese patient for surgery are assessing the patient's motivation (Table 2 ) and psychosocial risk factors (Table 3) , and making sure the candidate fully comprehends the mechanisms of the two types of operations: gastric restrictive and diversionary (Figure 1) . Because of the obstructive component of both types of gastric operations it is imperative that the candidate has learned and understood the 'Rules of eating' and the 'Rules of vomiting' (Table 4) . These simple rules, though self-explanatory, are not self-evident and can explain behavioral and anatomical failures.
With regard to realistic expectations of maintained weight loss, there is considerable confusion about 'goal weights' among surgeons 27 and other health-care professionals, 28 which can negatively influence the patient. The concept of 'ideal' or 'desirable' weight for height has been developed from mortality statistics of large populations. Within such populations there are only few individuals who have lost medically significant amounts of weight. There is abundant literature demonstrating increased mortality associated with (voluntary) weight loss, but the data has not been stratified for starting weight, for absolute weight loss, for duration of weight maintenance or for age. Thus, it is not possible to determine an evidence-based ideal or desirable (ie goal) weight for a person who has been severely obese. It is inappropriate to discuss 'normalization' of body weight 28 without having a definition of 'normal'! Based on body composition data in patients with surgically induced weight loss it appears that loss of 100% of excess weight (thus achieving a life-insurance weight standard) is associated with loss of lean body mass as in frank malnutrition. 29, 30 Depending on initial weight and the rate of weight 28, 31 and it is not likely that there will be any resolution to the problem given the heterogeneity of the obese population, variations in surgical methods and the accuracy of diagnosing the condition. Prevalence of BED is very different in surgical candidates assessed prior to surgery than in post-operative patients reporting on their pre-operative behavior. They are more likely to be honest about their original eating behavior postoperatively (Kral JG, unpublished observations).
Summary
Indications for anti-obesity surgery are broadening owing to increased safety, recognition of the severity of the disease, and its intractability using non-operative methods. However, anti-obesity surgery differs from other surgery. Because it is behavioral surgery, patient selection is critical, with demands beyond those of other operations. Pre-and postoperative education determines outcome of bariatric surgery to a much greater degree than in other surgery. Though many potential outcome predictors have been identified, there are as yet no validated long-term predictors of 'success', regardless of the definition of success. In the absence of predictors, it is reasonable to use a staged approach in bariatric surgery by employing minimally invasive, reversible, restrictive operations in the lightest patients, with the milder eating disorder, and reserving increasingly malabsorptive bypass procedures for heavier patients and as a rescue procedure for those that have failed prior surgery (Figure 2 
21
). Remaining challenges to the field of bariatric surgery include: (1) inventing methods to analyze behavioral parameters that may serve as outcome predictors; (2) designing prospective observational studies with sufficient power to determine optimal amounts and rates of weight loss; (3) formulating indications for reoperating for weight regain; and (4) determining criteria for performing gastric restrictive or diversionary procedures in young people. Though surgical treatment is more cost-effective and has a better risk -benefit ratio than other treatment for moderate and severe obesity, there is much room for improvement.
